The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Vernyuk M.A.
P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia
Chervontseva A.M.
P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia
Cherkashina I.V.
P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia
Khairullina L.S.
P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia
Fedenko A.A.
P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia
Relapse of primary mediastinal B-cell lymphoma with isolated central nervous system involvement: risk factors and search for personalized therapy
Journal: P.A. Herzen Journal of Oncology. 2024;13(2): 39‑45
Views: 692
Downloaded: 3
To cite this article:
Vernyuk MA, Chervontseva AM, Cherkashina IV, Khairullina LS, Fedenko AA. Relapse of primary mediastinal B-cell lymphoma with isolated central nervous system involvement: risk factors and search for personalized therapy. P.A. Herzen Journal of Oncology.
2024;13(2):39‑45. (In Russ.)
https://doi.org/10.17116/onkolog20241302139
Relapse of primary mediastinal B-cell lymphoma (PMBCL) with isolated central nervous system (CNS) involvement is a rare event and presents a clinical problem. Prognostic risk factors for CNS relapse in PMBCL are insufficiently studied. Most studies indicate the predictive significance of extranodal involvement, particularly in the kidneys and adrenal glands. Optimal prevention and therapy for PMBCL relapse in the CNS are undefined and conducted by analogy with primary CNS lymphoma. However, considering the biological characteristics of PMBCL and the high effectiveness of new therapeutic options for systemic relapses, their integration into the treatment of relapses with CNS involvement seems reasonable. We present a clinical case of isolated relapse of PMBCL in the CNS with an 8-year relapse-free observation period.
Keywords:
Authors:
Vernyuk M.A.
P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia
Chervontseva A.M.
P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia
Cherkashina I.V.
P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia
Khairullina L.S.
P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia
Fedenko A.A.
P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia
Received:
13.12.2023
Accepted:
28.12.2023
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.